Swiss pharmaceutical company Novartis Pharma AG (SIX:NOVN) (NYSE:NVS) said on Monday that it will present data from 19 abstracts across its cardiovascular portfolio at the 2025 European Society of Cardiology (ESC) Congress in Madrid from 29 August to 1 September 2025.

"The latest data we are presenting at ESC will showcase how Novartis is pioneering groundbreaking treatments that can transform cardiovascular outcomes," said Ruchira Glaser, M.D., global head of the Cardiovascular, Renal and Metabolic Development Unit at Novartis. "With established treatments Entresto and Leqvio, we continue to explore new ways to improve patient care whilst also investigating broader populations who may benefit. With promising pipeline assets, pelacarsen and abelacimab, we are tackling areas of significant unmet need to address the myriad of factors that cause or worsen heart disease."

Included in the presentations are two VictORION studies, highlighting Leqvio's impact on patient quality of life, and as a cholesterol lowering monotherapy.

The Lp(a)FRONTIERS APHERESIS study assesses the effect of pelacarsen on reducing need for lipoprotein apheresis -- a cholesterol removal procedure similar to dialysis, while the PARACHUTE-HF study highlights the efficacy and safety of Entresto to treat heart failure with reduced ejection fraction due to chronic Chagas disease.

Additional presentations assess the safety of new pipeline asset abelacimab in atrial fibrillation.